Business
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nTotal product revenue increased 40% YoY to $74 million\n\nRecorlev® revenue grew 109% YoY to $37 million\n\nUpdating full-year 2025 total revenue guidance to $285-$290 million; previously $280-$290 million\n\nHosts conference call and webcast today at 8:30 a.m. ET\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025.\n\n“We delivered another record-breaking quarter, driven by increased patient demand across all three products,” said John Shannon, Chief Executive Officer. “Total product revenue grew 40% year-over-year, highlighting the strength of our portfolio and the meaningful difference we’re making in the lives of patients and providers alike. Recorlev led the way, with revenue growing 109% to $37 million, further validating its significant growth potential.\"\n\nShannon continued, \"Our year-to-date performance underscores the strength of our growth engine and the effectiveness of our strategic execution. With momentum continuing to build across the business, we are updating our 2025 total revenue guidance to $285-$290 million, which implies 42% growth at the midpoint compared to last year. As we progress through the final quarter, our focus remains on executing and investing in opportunities that will propel sustained growth into 2026 and beyond.\"\n\nThird Quarter 2025 Highlights\n\n\n\n \n\n\n\nThree months ended\nSeptember 30,\n\n\n\n \n\n\n\nChange\n\n\n\n\n\n \n\n\n\n2025\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n$\n\n\n\n%\n\n\n\n\n\nProduct revenue (in thousands):\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nRecorlev\n\n\n\n$\n\n\n\n36,975\n\n\n\n \n\n\n\n$\n\n\n\n17,726\n\n\n\n \n\n\n\n$\n\n\n\n19,249\n\n\n\n \n\n\n\n108.6\n\n\n\n \n\n\n\n\n\nGvoke\n\n\n\n \n\n\n\n25,151\n\n\n\n \n\n\n\n \n\n\n\n22,942\n\n\n\n \n\n\n\n \n\n\n\n2,209\n\n\n\n \n\n\n\n9.6\n\n\n\n \n\n\n\n\n\nKeveyis\n\n\n\n \n\n\n\n11,937\n\n\n\n \n\n\n\n \n\n\n\n12,193\n\n\n\n \n\n\n\n \n\n\n\n(256\n\n\n\n)\n\n\n\n(2.1\n\n\n\n)\n\n\n\n\n\nProduct revenue, net\n\n\n\n \n\n\n\n74,063\n\n\n\n \n\n\n\n \n\n\n\n52,861\n\n\n\n \n\n\n\n \n\n\n\n21,202\n\n\n\n \n\n\n\n40.1\n\n\n...